Moderna Inc. Faces Stock Downturn Following FDA Official's Resignation

In a startling development, Moderna Inc.'s shares experienced a sharp decline of over 13% in premarket trading this Monday. This downturn comes in the wake of the resignation of Peter Marks, the Food and Drug Administration's (FDA) leading vaccine official.

According to a spokesperson from the Department of Health and Human Services, Marks was faced with a stark ultimatum: resign or face termination. Insights from a source close to the matter reveal that the Trump administration played a pivotal role in his departure.

Market Reaction: By 7:36 am ET, Moderna's stock had fallen by 13.56%, trading at $26.76 per share, signaling investor unease in the wake of these developments.